Results 161 to 170 of about 30,645 (194)
Some of the next articles are maybe not open access.

Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa‐2b in HBeAg‐positive patients

Journal of Gastroenterology and Hepatology, 2010
AbstractBackground and Aim:  To evaluate the usefulness of quantitative hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) for predicting HBeAg seroconversion in chronic hepatitis B patients treated with conventional interferon (IFN) alfa‐2b or PegIFN alfa‐2b.Methods:  Fifty‐eight patients were enrolled; 29 for the training group and
Hui, Ma, Rui-Feng, Yang, Lai, Wei
openaire   +2 more sources

HBeAg Seroconversion in Children Infected During Early Childhood With Hepatitis B Virus [PDF]

open access: yesJournal of Clinical Virology, 2012
Seroconversion of hepatitis B e-antigen (HBeAg) to anti-HBe is associated with lower viral load and liver diseases.The purpose of this study was to assess the seroconversion rate of HBeAg to anti-HBe in children who acquired hepatitis B virus (HBV) infection during early childhood.From September 1990 to December 2010, 139 HBeAg-positive children were ...
Ali Bijani
exaly   +3 more sources

Effect of virologic response on posttreatment durability of lamivudine-induced HBeAg seroconversion

Journal of Hepatology, 2001
Lamivudine‐induced HBeAg seroconversion may not be durable in Korean patients with hepatitis B virus (HBV) infection. It is unknown whether virological response during lamivudine treatment affects the post‐treatment outcome. We retrospectively analysed 124 consecutive HBeAg‐positive chronic hepatitis B (CHB) patients treated with lamivudine. Lamivudine
K M, Lee   +5 more
openaire   +3 more sources

Predictive Factors for Early HBeAg Seroconversion in Acute Exacerbation of Patients With HBeAg-Positive Chronic Hepatitis B

Gastroenterology, 2009
This study aimed to identify the predictors for early hepatitis B e antigen (HBeAg) seroconversion following acute exacerbation (AE) in patients with HBeAg-positive chronic hepatitis B (CHB).A total of 151 patients with HBeAg-positive CHB and AE were consecutively enrolled. AE was defined as an elevation of alanine aminotransferase level to more than 5
Hyoung Su, Kim   +6 more
openaire   +2 more sources

Different Models of HBeAg Seroconversion Predicated by On-Treatment ALT and HBV DNA Profiles

Journal of Viral Hepatitis, 2009
Summary.  Pretreatment alanine transaminase (ALT) elevation may be used as a predictor for higher hepatitis B e antigen (HBeAg) seroconversion in chronic hepatitis B patients. However, the role of dynamic changes of on‐treatment ALT for seroconversion is unknown.
Hong You, Xiaojuan Ou, Baoen Wang
exaly   +3 more sources

Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion

Hepatology International, 2012
We investigated whether the combined presence and evolution of hepatitis B virus (HBV) mutant strains in the hepatitis B e antigen (HBeAg)-positive status can predict clinical outcomes after HBeAg seroconversion.One hundred and eighty-six patients with spontaneous HBeAg seroconversion were enrolled into this longitudinal study.
Chien-Hung, Chen   +6 more
openaire   +2 more sources

Prediction of spontaneous HBeAg seroconversion in HBeAg‐positive chronic hepatitis B patients during the immune clearance phase

Journal of Medical Virology, 2014
Spontaneous hepatitis B virus (HBV) e antigen (HBeAg) seroconversion is associated with reduced risk of liver‐related complications, but is poorly understood. In this study, 113 chronic hepatitis B patients in the immune active HBeAg‐positive phase were followed up for 76 weeks.
Guangjun, Song   +3 more
openaire   +2 more sources

ASSESSMENT OF PATIENTS WITH THERAPY INDUCED HBEAG SEROCONVERSION: A REAL-LIFE EXPERIENCE

Acta Medica Mediterranea, 2022
<p style="text-align:justify;font-size:9px;font-family:Times;"><b><i>Objective:</i></b><i> We aimed to evaluate clinical and laboratory features of chronic hepatitis B virus (HBV) patients before and after the therapy-induced Hepatitis B envelope antigen (HBeAg) seroconversion.<span> </span></
openaire   +1 more source

Profiles of HBV DNA, ALT and HBeAG status after stopping lamivudine in patients with HBeAg seroconversion

2010
AIM: To determine the virological and biochemical relapse rates in Chinese CHB patients with lamivudine-induced HBeAg seroconversion after stopping lamivudine therapy, and to identify significant viral or biochemical factors predictive of subsequent relapse.
Wong, DKH   +6 more
openaire   +2 more sources

Increase risk of HBeAg-negative chronic hepatitis B with older age at HBeAg seroconversion

2010
Background: Recent evidence suggests that delayed HBeAg seroconversion is associated with poorer outcome. We aim to determine the incidence of HBeAg-negative chronic hepatitis B (CHB) according to the age at which HBeAg seroconversion occurs. Methods: Chronic hepatitis B patients with natural HBeAg seroconversion and over 12 months follow-up after ...
Fung, JYY   +4 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy